Mirabegron displays anticancer effects by globally browning adipose tissues.

Metabolic reprogramming in malignant cells is a hallmark of cancer that relies on augmented glycolytic metabolism to support their growth, invasion, and metastasis. However, the impact of global adipose metabolism on tumor growth and the drug development by targeting adipose metabolism remain largely unexplored. Here we show that a therapeutic paradigm of drugs is effective for treating various cancer types by browning adipose tissues. Mirabegron, a clinically available drug for overactive bladders, displays potent anticancer effects in various animal cancer models, including untreatable cancers such as pancreatic ductal adenocarcinoma and hepatocellular carcinoma, via the browning of adipose tissues. Genetic deletion of the uncoupling protein 1, a key thermogenic protein in adipose tissues, ablates the anticancer effect. Similarly, the removal of brown adipose tissue, which is responsible for non-shivering thermogenesis, attenuates the anticancer activity of mirabegron. These findings demonstrate that mirabegron represents a paradigm of anticancer drugs with a distinct mechanism for the effective treatment of multiple cancers.

Analysis of the Efficacy and Safety of Teriparatide and Alendronate in the Treatment of Osteoporosis After Renal Transplantation.

INTRODUCTION: Both teriparatide and alendronate were used in the treatment of osteoporosis after renal transplantation. However, there are few studies comparing their application after renal transplant surgeries. This study was carried out to compare the effect of alendronate and teriparatide on bone mineral density in the treatment of osteoporosis after renal transplantation. METHODS: This is a retrospective cohort study of 153 patients who were diagnosed with osteoporosis after receiving renal transplantation, and received either alendronate or teriparatide treatment. The demographic patient information, changes in patients' quality of life, mobility and pain scores, serum biochemical markers and bone density of lumbar spine, hip and femoral neck were measured and compared between groups a year after treatment. RESULTS: there were no significant differences between the two groups concerning patient demographics such as age, gender and BMI. After a year of treatment, there were no significant differences between the two groups in biochemical markers such as serum calcium, phosphorus, creatinine and 25-OH Vitamin D (P > .05). BMD of lumbar spine, hip and femoral neck after the treatment was significantly higher in the teriparatide group than alendronate group (P < .05), while the incidence of adverse effects was higher in the teriparatide group than alendronate group (P < .05). CONCLUSION: teriparatide can be more effective than the alendronate in the treatment of osteoporosis in renal transplant patients, while having more adverse effects. DOI: 10.52547/ijkd.6475.